150:41
longevity
Comparing NAD-pathway supplementation (NR, NMN, IV NAD) against rapamycin and caloric restriction, Attia argues the experimental evidence (especially from the Interventions Testing Program) robustly supports rapamycin and caloric restriction as geroprotective, while NAD precursor supplementation lacks convincing lifespan or healthspan evidence beyond a possible skin-cancer signal — and both hosts agree that foundational behaviors (sleep, exercise, nutrition, emotional health) dwarf any supplement in impact on longevity.
Huberman's four-category framework for longevity approaches: behavioral dos-and-don'ts, calories/glucose/insulin/mTOR, targeting specific cellular pathways (e.g. NAD), and 'kitchen sink' stacking (Brian Johnson example).
Attia's three-category framework: essential behavioral factors (eating, sleeping, moving), exogenous molecules targeting specific disease processes (metformin, SGLT2i, GLP1 agonist, PCSK9i, statin, bempedoic acid), and geroprotective molecules that target aging hallmarks directly (rapamycin).
'Development is aging' — mTOR is robustly expressed from infancy through puberty, one of the most rapid aging phases of life, then tapers at puberty.
In modern society, living longer is mathematically equivalent to delaying the onset of chronic disease (cardiovascular, cerebrovascular, cancer, neurodegenerative, dementing, metabolic), since infection and childbirth complications are no longer primary mortality drivers.
Only two interventions — caloric restriction and rapamycin — have ever extended lifespan across all four model-organism categories (yeast, worms, flies, mammals); rapamycin shows uniform life extension unmatched by any other molecule.
Attia takes rapamycin 8 mg once weekly, cycling roughly two months on/one month off due to side effects (~10% of his rapamycin patients develop mouth sores).
The sirtuin/caloric-restriction hypothesis (that CR works through the sirtuin pathway) was falsified across multiple yeast strains: some strains respond to CR but not sirtuin overexpression, others the reverse, and a 2004 study (Kaplan & Kennedy) found the two effects were independent and additive, not synergistic.
Only one transgenic mouse model (SIRT6 overexpression) has shown a survival benefit, and only in males (10–15% longer life); females showed no extension.
NAD functions as a coenzyme/electron shuttle in 500–600 cellular pathways, is tightly regulated regardless of age, and is consumed as a substrate specifically by sirtuins during DNA repair.
Resveratrol, once believed to work through sirtuins and touted via the 'French Paradox,' showed 'categorically nothing' in ITP testing; achieving effective doses would require drinking one's body weight in wine daily.
What actually declines with age is not the total NAD pool but 'redox potential' — the ability to shuttle electrons — reflecting declining mitochondrial function, not NAD depletion per se.
NR crosses cell membranes directly; NMN carries an extra phosphate group that must be cleaved before uptake, giving NR stronger evidence as an effective oral NAD precursor over NMN (though IV NAD bypasses this via infusion since NAD itself is not orally bioavailable).
NR failed ITP testing entirely — no lifespan extension, no healthspan improvement, no change in blood NAD — while rapamycin, acarbose, SGLT2 inhibitors, and 17-alpha estradiol (in males) all extended lifespan in the same program.
A fatty-liver-disease trial of NR+pterostilbene ('Basis') found no primary-outcome effect; only a subanalysis restricted to a narrower baseline subgroup showed statistical significance, illustrating why 'statistical significance' must not be confused with 'clinical significance.'
The NMN vs. NR debate is characterized as a commercial rather than scientific dispute; the FDA classified NMN as an experimental drug (blocking supplement sales) after a company began drug trials with it, paralleling what happened with NAC.
The one 'real' NAD-precursor signal found was a 60–80% reduction in basal and squamous cell (not melanoma) skin carcinomas, which aligns with skin showing the largest age-related NAD decline of any tissue.
Rapamycin, taken daily, appears immunosuppressive, but pulsed (weekly) dosing — per Mannick & Klickstein's 2014 study on elderly subjects and flu vaccine response — appears to enhance immune function instead.
Popular 'biological age' tests (movement/camera-based, epigenetic clocks) show large day-to-day measurement noise and lack a proven predictive advantage over chronological age for remaining lifespan.
Ages 50–70 are framed as the 'critical decade' — the deciding window for building physiologic reserve (muscle, strength, resilience) before further decline compounds.
Both hosts extensively detail their personal supplement stacks (fish oil, vitamin D, creatine, magnesium, methyl folate/B12, probiotics, etc.) as distinguished sharply from unproven NAD precursors.
Huberman states he does not take NAD, NMN, or NR, explicitly because he does not believe they work — not for cost or convenience reasons — while remaining open to reversing that stance given new data.
The 'Titanic' analogy: emotional/mental health is the ship's heading (the fundamental factor), while sleep, exercise, and nutrition are the other core pillars, and supplement choices (like NAD precursors) are comparatively minor deck details (lobster vs. steak) that matter far less than the overall direction.
Huberman's four-category longevity framework — A taxonomy of longevity approaches: behavioral dos-and-don'ts, calories/glucose/insulin/mTOR management, targeting specific cellular pathways (like NAD), and 'kitchen sink' stacking of many interventions at once. Apply: Use it to categorize any longevity intervention under consideration (e.g. is this a behavioral change, a metabolic lever, a pathway-specific molecule, or part of a broad stack) before deciding whether to adopt it.
Attia's three-category framework (essential behavioral / exogenous disease-targeting / geroprotective) — A mutually exclusive, collectively exhaustive classification of interventions into mandatory behaviors (eating, sleeping, moving), drugs targeting specific disease processes (metformin, SGLT2i, PCSK9i, statin, bempedoic acid), and geroprotective molecules that target aging hallmarks directly (rapamycin). Apply: Sort any candidate intervention into one of the three buckets to judge whether it addresses baseline survival behavior, a specific disease risk, or the aging process itself, and weigh evidence accordingly.
Element electrolyte protocol — Huberman's daily hydration routine of 1–3 electrolyte packets each mixed with 16–32 oz water, starting immediately on waking. Apply: Sip one packet across the first 30 minutes after waking, add a second packet during the day, and a third if exercising or sweating heavily.
Eight Sleep temperature programming protocol — Using a smart mattress cover to program body temperature down at sleep onset and up before waking, since body temperature must drop 1–3° to fall/stay asleep and rise 1–3° to wake refreshed. Apply: Program the mattress cover to cool the bed at the start of the night and warm it near wake time to align with the body's natural sleep-wake temperature curve.
Levels CGM (continuous glucose monitor) protocol — Wearing a continuous glucose monitor to get real-time feedback on how specific foods affect blood glucose. Apply: Use CGM readings to time meals relative to workouts and sleep and to identify which foods spike glucose personally.
Zone 2 cardio — An exercise intensity zone that maximizes fat oxidation, cited as part of the essential behavioral movement category for longevity. Apply: Include Zone 2 intensity cardio sessions as part of a weekly aerobic training plan alongside higher-intensity aerobic work and resistance training.
Rapamycin dosing & cycling protocol — Attia's personal geroprotective regimen: 8 mg of rapamycin taken once weekly, cycled roughly two months on and one month off to manage side effects like mouth sores. Apply: If prescribed, follow a similarly pulsed weekly dosing schedule with planned off-cycles rather than continuous daily dosing, since pulsed dosing is linked to improved rather than suppressed immune function.
Knockout / knockin / transgenic mouse models (gain-of-function vs. loss-of-function) — Genetic techniques used to test gene function in longevity research: knockouts delete a gene, knockins/transgenics reintroduce or overexpress it (often tissue-specific via targeted enhancer insertion). Apply: Use these model distinctions to interpret longevity study claims — check whether a result comes from a gene deletion, an overexpression, or a tissue-restricted transgene before generalizing the finding.
Interventions Testing Program (ITP) — An NIH-funded rigorous testing pipeline that evaluates candidate longevity molecules in non-inbred mice, replicated in triplicate across three independent institutions. Apply: Treat ITP results as the most rigorous available benchmark when evaluating whether a longevity supplement or drug has real lifespan-extension evidence, favoring ITP-confirmed molecules (rapamycin, acarbose, SGLT2 inhibitors, 17-alpha estradiol) over ITP-failed ones (NR, metformin, fisetin).
Kaplan–Meier survival curve analysis — A statistical method for visualizing and comparing survival/lifespan across experimental groups over time. Apply: Use survival curve comparisons to assess whether an intervention produces a genuine, reproducible lifespan shift versus a marginal or non-significant one.
NAD/NADH electron shuttle & redox potential model — A biochemical framework describing NAD and NADH's primary role (99%) as electron shuttles in mitochondrial energy production, with 'redox potential' representing the tissue's electron-shuttling capacity, which declines with age due to mitochondrial dysfunction rather than NAD depletion. Apply: When evaluating NAD-boosting claims, ask whether an intervention improves mitochondrial function/redox potential (the actual age-related deficit) rather than just raising the static NAD pool.
Red light / near-infrared light therapy protocol (Glenn Jeffrey's method) — Exposing the aged eye (40+) to red or near-infrared light for a couple of minutes a few times per week to reduce reactive oxygen species and spare photoreceptor function. Apply: Apply brief, low-frequency red/near-infrared light exposure to the eyes as a low-risk intervention aimed at preserving vision-related mitochondrial function with age.
IV NAD infusion protocol — Intravenous administration of NAD (since oral NAD is not bioavailable and breaks down before reforming), typically run over 30 minutes to 3 hours at doses of 500–1000 mg, costing roughly $300–$1,000 per session. Apply: If considering IV NAD, be aware infusion rate affects acute side effects (nausea, cramping) and that clinical evidence for meaningful lifespan/healthspan benefit is currently lacking relative to its cost.
NR vs. NMN bioavailability and dosing comparison — A pharmacological comparison noting NR crosses the cell membrane directly while NMN must first be dephosphorylated, with NR typically dosed at 300–600 mg versus NMN's ~1500 mg, and NR claimed (commercially) to be ~25% more effective per milligram. Apply: When choosing between NR and NMN precursor supplements, weigh the membrane-permeability and dosing-efficiency argument favoring NR, while recognizing no head-to-head blood-NAD trial has directly settled the comparison.
GRAS (Generally Recognized As Safe) supplement classification — An FDA designation (held by NR) that permits a compound to be sold as a supplement without FDA oversight of manufacturing, contrasted with NMN's post-clinical-trial reclassification as an investigational drug. Apply: Recognize that GRAS status confers legal sale ability, not proof of efficacy, and that FDA supplement/drug classification can shift based on commercial trial activity rather than new safety or efficacy data.
Statistical significance vs. clinical significance framework — A distinction emphasized throughout: a result can be statistically significant (unlikely due to chance) yet clinically meaningless (too small to matter for actual health outcomes), as illustrated by blood-pressure and hepatic-fat subanalysis examples. Apply: Before accepting a supplement or drug claim backed by a 'statistically significant' study, check the actual effect size against a clinically meaningful threshold, and be suspicious of results only reachable via subgroup/subanalysis of a null primary outcome.
Pulsed vs. continuous dosing for immune modulation — The finding that daily rapamycin dosing suppresses immune function while weekly pulsed dosing appears to enhance it (based on Mannick & Klickstein's 2014 elderly flu-vaccine study), reframing rapamycin as an immune modulator rather than pure suppressant. Apply: When considering mTOR-inhibitor dosing, evaluate the dosing schedule (continuous vs. pulsed) as a variable that changes the drug's immune effect, not just the total dose.
Biological age / movement testing (camera-based assessment) — A commercial fitness assessment using a multi-camera system measuring jump height, throw distance, and balance to output a 'movement age,' which showed high day-to-day variability for the same person. Apply: Treat such biological-age scores as directionally suggestive at best, not precise, and judge any aging metric by whether it out-predicts chronological age for remaining lifespan (the stated 'gold standard' test) before trusting it.
'Life in Weeks' chart with a Vigor scale — A personal tracking tool visualizing an estimated full lifespan in weeks alongside a self-rated 0–10 'vigor' score tracked roughly every two months, adjusted for life stressors and positive events. Apply: Build a similar lifespan-visualization chart and log a periodic subjective vigor score to identify which behaviors or life phases raise or lower personal energy/vitality over time.
Radiation exposure (millisievert) risk framework — A comparative scale of annual radiation exposure (NRC recommended limit <50 mSv/year; sea level ~1 mSv/year; CT angiogram 3–15 mSv; nuclear workers ~500 mSv/year with no proven increased cancer risk) used to contextualize common exposure sources like flights and scanners. Apply: Use these mSv benchmarks to judge whether a specific radiation exposure (airport scanner, flight, DEXA scan, CT) is meaningfully risky, generally concluding common exposures are far below levels associated with harm.
The 'critical decade' concept (ages 50–70) — A framing that the decades from 50–70 are the pivotal window where aging effects (sleep quality, strength, recovery) become most consequential and where building physiologic reserve most determines later-life trajectory. Apply: Prioritize consistent self-care, recovery, and physiologic-reserve-building (strength, sleep, mindful eating) specifically during this decade window rather than deferring it.
Exercise timing / circadian temperature protocol — A hypothesis and personal practice that completing exercise before 9 a.m. (ideally near the circadian temperature nadir, e.g. 4:30–5 a.m.) yields sustained all-day energy, versus mid/late-morning workouts that deplete afternoon energy. Apply: Experiment with shifting workout timing earlier (before 9 a.m.) and observe its effect on same-day energy levels as a personalized variable, not just a fixed prescription.
Homocysteine management via methyl folate + methyl B12 — A supplementation approach targeting elevated homocysteine, which is thought to impair clearance of ADMA/SDMA, in turn impairing nitric oxide synthase and vascular health; methyl folate and methyl B12 lower homocysteine and are hypothesized to indirectly raise nitric oxide synthase activity. Apply: Consider methyl folate plus methyl B12 supplementation (avoiding excess B6 due to nerve-damage risk) to address elevated homocysteine as part of vascular risk management.
Magnesium multi-form ('carpet bombing') strategy — Taking three different magnesium forms simultaneously (L-threonate/L8, slow-mag chloride, and magnesium oxide) for combined bowel-function and cramp-prevention benefits. Apply: Combine multiple magnesium forms rather than relying on a single type when targeting both bowel regularity and muscle-cramp prevention.
Anaerobic-bacteria probiotic selection (Pendulum/Akkermansia) — A selection criterion for probiotics requiring anaerobic bacterial strains (like Akkermansia, which works via a GLP1/butyrate pathway) since aerobic bacteria are argued to have no meaningful probiotic value, with Pendulum cited as the only company manufacturing anaerobic strains under pharma-grade GMP. Apply: When choosing a gut-health probiotic, check whether it contains anaerobic strains manufactured under nitrogen-infused, GMP-compliant conditions rather than standard aerobic probiotic formulations.
Attia's daily supplement stack — A itemized personal regimen including fish oil (>1g EPA/day), vitamin D3 (5,000 IU, titrated by blood level), Tonka Ali (to lower SHBG), green tea/yerba mate for caffeine, NMN/NR (irregularly), 10g/day creatine monohydrate, sleep-support magnesium/apigenin/theanine/inositol, whey protein, and occasional shilajit and alpha-GPC pre-workout. Apply: Use it as a reference template for a longevity-oriented supplement stack, noting which items Attia takes consistently (creatine, fish oil, D3) versus irregularly (NMN/NR, shilajit) as a signal of his actual conviction level in each.
Portfolio conviction principle — Huberman's heuristic that a person's true beliefs are revealed by what they actually do ('what's in your portfolio') rather than what they claim to believe. Apply: Judge the credibility of any health claim (including one's own) by checking whether the claimant actually uses the intervention themselves, not just by their stated endorsement.
The Titanic analogy / four-pillar health framework — A metaphor where emotional/mental health represents the ship's heading (the dominant directional factor), sleep, exercise, and nutrition are the other essential pillars, and supplement choices (like NAD precursors) are minor details ('lobster vs. steak') that matter far less than the overall direction. Apply: Prioritize decisions and effort according to this hierarchy — address emotional health, sleep, exercise, and nutrition first, and treat supplement optimization as a secondary refinement, not a primary lever.
The sirtuin-caloric-restriction link, long assumed causal, was empirically falsified by strain-dependent yeast experiments showing the two pathways are independent and merely additive — a foundational assumption in longevity science that didn't hold up.
The popular narrative that 'NAD declines with age, so raising NAD should help' conflates two different things: the actual finding is that redox potential (electron-shuttling capacity tied to mitochondrial function) declines, not that the total NAD pool disappears — undermining the basic rationale for NAD-boosting supplements.
NMN's chemical structure (requiring dephosphorylation before crossing cell membranes) versus NR's direct membrane permeability is presented as a bioavailability argument favoring NR, yet a head-to-head blood-NAD comparison study using oral NR vs. sublingual NMN has, to Attia's knowledge, never been done.
The FDA's move to reclassify NMN as an investigational drug (after a company started a drug trial with it) mirrors a similar precedent with NAC — showing how commercial trial strategy, not biology, can determine a molecule's legal supplement status.
Despite extensive theorizing about rapamycin's mTOR mechanism, Attia states his real conviction comes from the experimental/ITP data rather than the mechanistic story — an explicit evidentiary hierarchy he applies unevenly to NAD (where he says the experimental data is 'sorely lacking').
Rapamycin's immune effect flips sign depending on dosing schedule: daily dosing suppresses immunity (matching pre-2014 assumptions from transplant medicine), while once-weekly pulsed dosing appears to enhance vaccine response in elderly subjects — reversing the field's earlier framing of rapamycin as purely immunosuppressive.
The only positive finding across all the NAD-precursor human data reviewed is a large (60–80%) reduction specifically in basal/squamous cell skin carcinomas, not melanoma — and this happens to track with skin being the tissue with the largest age-related NAD decline, offering the one plausible mechanistic-to-clinical throughline in an otherwise weak evidence set.
A subanalysis of a hepatic-fat clinical trial only reached significance when restricted to participants below a specific baseline threshold (27% hepatic fat) — offered as a textbook illustration of how data-mining a null primary outcome can manufacture a 'significant' but clinically meaningless result.
Rapamycin has essentially no commercial upside (it's off-patent, costing ~$40/week at a therapeutic geroprotective dose) which the source frames as explaining the comparative lack of marketing/hype around it relative to heavily promoted, patent-protected-adjacent NAD precursor products.
Huberman frames his supplement choices as a 'portfolio' test of conviction ('don't tell me what you think, show me what's in your portfolio') and applies it to himself by pointedly not taking NAD/NMN/NR despite years of exposure to the topic, while still taking numerous other supplements he does believe in.
Biological-age tests (a camera-based movement assessment) produced wildly inconsistent scores for the same person on different days, suggesting the 'gold standard' question — whether biological age outperforms chronological age at predicting remaining lifespan — remains empirically unresolved despite commercial popularity of such tests.
«for people that want to live as long as possible I think there are at least four categories of approaches broadly speaking»
— 06:56
«development is aging»
— 10:17
«the longer we delay the onset the longer we will live full stop»
— 14:24
«there are only two interventions full stop that have ever extended life across those four categories of UK chariots caloric restriction and rap ay»
— 20:26
«NAD and nadh basically play catch with electrons and that's 99% of what NAD is doing in the body»
— 26:03
«there's no evidence whatsoever that cerin have anything to do with chloric restriction and vice versa»
— 38:10
«you would need to be drinking your body weight and wine a day to get the doses of RIS veratrol that were needed to produce this effect»
— 51:43
«people enjoy the comfort of opinion without the discomfort of thought»
— 65:00
«never confuse statistical significance with clinical significance»
— 82:05
«if you have to resort to really interesting statistical machinations to see something there probably isn't something very interesting there»
— 85:04
«I think the whole NMN/NR debate is irrelevant I think it's just a commercial debate I think it's literally just posturing about how can I carve out a different Market I don't think there's a scientific reason to favor one over the other»
— 86:31
«if you take rapamycin as a human at least every day it seems to suppress your immune system but if you just pulse it once a week as they did in that study it seems to improve immune function»
— 104:35
«this is the critical decade it's in your 50s to your 60s and in your 60s to your 70s that I think is is the deciding time»
— 119:01
«your mental health is the equivalent of what Direction was the Titanic going with respect to the iceberg»
— 146:17
«I passionately do not believe they do anything for me and why would I waste time money anything on something that I really don't believe makes a difference»
— 147:41
«I will reserve the right to change my my mind for the rest of my life in the presence of new data»
— 148:01
Reception
Polarized reception with significant controversy surrounding the guest; negative comments are more highly engaged, with multiple viewers demanding removal over alleged issues, though a smaller group of supporters appreciates the episode.
The episode models an evidence-hierarchy approach to a hyped supplement category — leaning on ITP data, statistical-vs-clinical-significance distinctions, and mechanistic bioavailability arguments to systematically deflate the case for NAD precursor supplementation relative to rapamycin and caloric restriction — but its exhaustive mechanistic digressions (yeast strain genetics, electron transport chemistry) make it a demanding, technical listen relative to its practical payoff.
150:41